Return to Vaccination News Home Page __» Right-click to "open in new window"
Subscribe to the Vaccination NewsLetter
View past & current Scandals (columns by Sandy Mintz)
Search This Site using keywords
http://www.jimmunol.org/cgi/content/abstract/171/3/1596
|
The Journal of Immunology, 2003, 171: 1596-1601.
Copyright © 2003 by The
American Association of Immunologists
Department of Microbiology and Immunology, Temple University School of Medicine, Philadelphia, PA 19140
After exposure to subtoxic doses of heavy metals such as mercury,
H-2s mice develop an autoimmune syndrome consisting of the
rapid production of IgG autoantibodies that are highly specific for
nucleolar autoantigens and a polyclonal increase in serum IgG1
and IgE. In this study, we explore the role of two inhibitory
immunoreceptors, CTLA-4 and Fc
RIIB, in the regulation of mercury-induced
autoimmunity. In susceptible mice treated with mercuric chloride
(HgCl2), administration of a blocking anti-CTLA-4 Ab resulted
in a further increase in anti-nucleolar autoantibodies and in
total serum IgG1 levels. Furthermore, in some DBA/2 mice, which are
normally resistant to heavy metal-induced autoimmunity, anti-CTLA-4
treatment leads to the production of anti-nucleolar Abs, thereby
overcoming the genetic restriction of the disease. In mice deficient
for the Fc
RIIB,
HgCl2 administration did not trigger autoantibody
production, but resulted in an increase in IgE serum levels. Taken
together, these results indicate that different inhibitory mechanisms
regulate various manifestations of this autoimmune syndrome.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Return to Vaccination News Home Page __» Right-click to "open in new window"
DISCLAIMER: All information, data, and material contained, presented, or provided here is for general information purposes only and is not to be construed as reflecting the knowledge or opinions of the publisher, and is not to be construed or intended as providing medical or legal advice. The decision whether or not to vaccinate is an important and complex issue and should be made by you, and you alone, in consultation with your health care provider.